(Prudent Press Agency)---WHITEHOUSE STATION, N.J., U.S.A.--Merck Sharp & Dohme (MSD) announced today that TREDAPTIVE (nicotinic acid/laropiprant, MSD) 1 g/20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has been approved for marketing in the European Union (EU), Iceland and Norway. TREDAPTIVE combines nicotinic acid (niacin) and laropiprant, a novel flushing pathway inhibitor. In clinical studies involving more than 4,700 patients, TREDAPTIVE reduced LDL-cholesterol (LDL-C, or "bad" cholesterol) levels, raised HDL-cholesterol (HDL-C, or "good" cholesterol) levels and decreased triglycerides (a type of fat in the blood). High LDL-C, low HDL-C and elevated triglycerides are risk factors associated with heart attacks and strokes. ...
Anytime
(Prudent Press Agency)---WHITEHOUSE STATION, N.J., U.S.A.--Merck Sharp & Dohme (MSD) announced today that TREDAPTIVE (nicotinic acid/laropiprant, MSD) 1 g/20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has been approved for marketing in the European Union (EU), Iceland and Norway. TREDAPTIVE combines nicotinic acid (niacin) and laropiprant, a novel flushing pathway inhibitor. In clinical studies involving more than 4,700 patients, TREDAPTIVE reduced LDL-cholesterol (LDL-C, or "bad" cholesterol) levels, raised HDL-cholesterol (HDL-C, or "good" cholesterol) levels and decreased triglycerides (a type of fat in the blood). High LDL-C, low HDL-C and elevated triglycerides are risk factors associated with heart attacks and strokes. ...